News & Updates

Two-year data support brolucizumab for diabetic macular oedema

17 May 2024 by

The 100-week results of the phase III KESTREL and KITE studies reflect the long-term efficacy and durability of brolucizumab in improving visual and anatomical outcomes in patients with diabetic macular oedema (DMO).

Two-year data support brolucizumab for diabetic macular oedema

17 May 2024

Type 1 diabetes linked to lower fitness capacity

17 May 2024

People with type 1 diabetes appear to have lower fitness capacity relative to their peers without the condition, despite having similar levels of physical activity, according to a study.

Type 1 diabetes linked to lower fitness capacity

17 May 2024

Menopausal hormone therapy may protect against gastric cancer in Asians

16 May 2024 by

The use of menopausal hormone therapy among postmenopausal Asian women has been linked to a reduced risk of gastric cancer in a study.

Menopausal hormone therapy may protect against gastric cancer in Asians

16 May 2024

LVDD tied to dyspnoea, poorer survival in SSc-ILD patients

16 May 2024

Left ventricular (LV) diastolic dysfunction (LVDD) in systemic sclerosis (SSc)-associated interstitial lung disease (ILD) shows a greater association with traditional LVDD than SSC-specific risk factors, reveals a study. Of note, SSc-ILD patients with LVDD appear to have worse dyspnoea and survival.

LVDD tied to dyspnoea, poorer survival in SSc-ILD patients

16 May 2024

Many female lung cancer patients left out by screening criteria: study

16 May 2024 by

The National Lung Screening Trial (NLST) in Singapore falls short of identifying some individuals, particularly women, who are at an increased risk of developing lung cancer, according to a study. However, those who meet the criteria may derive significant benefits from the screening.

Many female lung cancer patients left out by screening criteria: study

16 May 2024

Selective aldose reductase inhibitor for DCM disappoints in trial

16 May 2024

Treatment with AT-001, a highly selective aldose reductase inhibitor, for 15 months seems no better than placebo in improving exercise capacity among individuals with diabetic cardiomyopathy (DCM) and impaired exercise capacity, a study has shown.

Selective aldose reductase inhibitor for DCM disappoints in trial

16 May 2024

Long-term data strengthen TAK-003 potential against dengue

16 May 2024 by

The live-attenuated tetravalent dengue vaccine TAK-003 showed cumulative long-term efficacy in preventing symptomatic dengue caused by all four dengue virus (DENV) serotypes among previously exposed children and adolescents, and by DENV-1 and DENV-2 in dengue-naïve participants in eight* dengue-endemic countries, a study has shown.

Long-term data strengthen TAK-003 potential against dengue

16 May 2024

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

16 May 2024 by

Immunotherapy (IO) has become part of standard care for early-stage non-small-cell lung cancer (NSCLC), necessitating a multidisciplinary approach for optimum treatment. At a symposium conducted during the Hong Kong Thoracic Society and CHEST Autumn Respiratory Seminar (HKTS/CHEST ARS) 2023, Mr Naveed Alam, Consultant Thoracic Surgeon at St. Vincent Hospital in Melbourne, Australia, shared promising results of the IMpower010 trial of adjuvant atezolizumab, emphasized the importance of early involvement of multidisciplinary teams (MDTs) in patient care, and discussed surgeons’ concerns regarding neoadjuvant IO, including high surgical attrition rate, fibrosis, and adhesions.

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

16 May 2024

HbA1c variability linked to serious infections

16 May 2024

Fluctuations in HbA1c levels in between clinic visits may put individuals with type 2 diabetes (T2D) at increased risk of serious infections, according to a study.

HbA1c variability linked to serious infections

16 May 2024

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

16 May 2024 by

An 81-year-old homebound, obese (BMI, 31 kg/m²) female complained of dyspnoea on exertion and exercise intolerance in 2023. The patient often needed to stop after walking for a distance of two blocks or climbing eight steps of stairs (New York Heart Association [NYHA] functional class II), which limited her daily and social activities.

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

16 May 2024

News & Updates

Filter by Specialty:

Specialty:

Two-year data support brolucizumab for diabetic macular oedema

Two-year data support brolucizumab for diabetic macular oedema

Type 1 diabetes linked to lower fitness capacity

Type 1 diabetes linked to lower fitness capacity

Menopausal hormone therapy may protect against gastric cancer in Asians

Menopausal hormone therapy may protect against gastric cancer in Asians

LVDD tied to dyspnoea, poorer survival in SSc-ILD patients

LVDD tied to dyspnoea, poorer survival in SSc-ILD patients

Many female lung cancer patients left out by screening criteria: study

Many female lung cancer patients left out by screening criteria: study

Selective aldose reductase inhibitor for DCM disappoints in trial

Selective aldose reductase inhibitor for DCM disappoints in trial

Long-term data strengthen TAK-003 potential against dengue

Long-term data strengthen TAK-003 potential against dengue

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

Early-stage NSCLC: Why surgeons’ perspectives matter in the era of perioperative IO

HbA1c variability linked to serious infections

HbA1c variability linked to serious infections

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF

SGLT2 inhibitor as GDMT in an elderly female with chronic HFpEF